Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Nigel T. J. O'Connor"'
Publikováno v:
British journal of neurosurgery.
A 77-year old female with a history of neurofibromatosis type 2 (NF2) was diagnosed with a spinal schwannoma that was managed conservatively over a decade. During this time, follow up imaging revealed this lesion had been growing and the patient had
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::213d04700f88bd2ea44e42caf721e3f0
https://pubmed.ncbi.nlm.nih.gov/32188281
https://pubmed.ncbi.nlm.nih.gov/32188281
Autor:
Nigel T. J. O’Connor, Jeffrey R. Neilson, Philip Gothard, B Kishore, Claire Shannon-Lowe, Martin Rowe, Christopher P. Fox
Publikováno v:
Clinical Infectious Diseases. 51:66-69
Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (HLH) is a rare and aggressive disease usually encountered in the context of primary EBV infection. In most analyzed cases, EBV has been found predominantly in T cells. We describ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aea8f187cc0155265b66aa7876a99414
https://doi.org/10.1086/653424
https://doi.org/10.1086/653424
Autor:
Nnenna Osuji, S. A. Johnson, Claire Dearden, Juan Garcia-Talavera, Monica Else, Estella Matutes, Daniel Catovsky, Ama Z. S. Rohatiner, Francesco Lauria, Francesco Forconi, Nigel T. J. O’Connor, A P Haynes
Publikováno v:
British Journal of Haematology. 145:733-740
Hairy cell leukaemia (HCL) was first described 50 years ago. Median survival was then 4 years. The purine analogues, introduced in the 1980s, transformed this prognosis. We reviewed data retrospectively from 233 patients, treated with pentostatin (n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::777e370c360d1b95dcfcecd89aacf38b
https://doi.org/10.1111/j.1365-2141.2009.07668.x
https://doi.org/10.1111/j.1365-2141.2009.07668.x
Autor:
Michael J. Griffiths, Nicola Foster, Norman Pratt, Kajsa Paulsson, Tracy Stubbs, Michael J. Groves, Nigel T. J. O’Connor, Sudhir Tauro, Mark Sales, Dominic J. McMullan, Joan Cunningham, Suriya Begum
Publikováno v:
British journal of haematology. 148(6)
A proportion of cytogenetic abnormalities in myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) may escape detection by high-resolution genomic technologies, but can be identified by conventional cytogenetic and molecular analysis. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd03da5f1d125ea0ffa22814a03c6558
https://pubmed.ncbi.nlm.nih.gov/20064152
https://pubmed.ncbi.nlm.nih.gov/20064152
Autor:
Nigel T. J. O’Connor, Ann Borley
Publikováno v:
Current medical research and opinion. 25(3)
Amphotericin B lipid complex (ABLC), a lipid-based formulation of amphotericin B, is an effective treatment for fungal infections, but is associated with mild to moderate drug delivery reactions (DDRs), such as fever, rigors and chills, in some patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0c1c4a2728c40a9d7f8aa68bbc6f12d
https://pubmed.ncbi.nlm.nih.gov/19196219
https://pubmed.ncbi.nlm.nih.gov/19196219
Autor:
Claire Shannon-Lowe, Philip Gothard, Nigel T. J. O’Connor, Martin Rowe, Jeffrey R. Neilson, Alan B. Rickinson, Christopher P. Fox, Bhuvan Kishore
Publikováno v:
Blood. 114:3672-3672
Abstract 3672 Poster Board III-608 Introduction Epstein Barr virus (EBV) is predominantly B lymphotrophic both in-vitro and in vivo, where in immunocompetent individuals the virus persists asymptomatically in the B lymphoid compartment under host T c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a219f2495eb0a6dfdf192ba9899eddd
https://doi.org/10.1182/blood.v114.22.3672.3672
https://doi.org/10.1182/blood.v114.22.3672.3672
Autor:
Estella Matutes, Claire Dearden, Daniel Catovsky, Ama Z. S. Rohatiner, Nigel T. J. O’Connor, S. A. Johnson, Monica Else, Nnenna Osuji, A P Haynes
Publikováno v:
Blood. 112:2101-2101
Background: In a previous review of hairy cell leukemia (HCL) patients we found no difference in efficacy between cladribine and pentostatin [Else et al, Cancer 104:2442- 8; 2005]. With longer follow-up (median 15.4 years since diagnosis) we aimed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28c81b6ef72e5022c4264c838e832308
https://doi.org/10.1182/blood.v112.11.2101.2101
https://doi.org/10.1182/blood.v112.11.2101.2101